Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline

The wild-type SARS-CoV-2 Spike-based vaccines authorized so far have reduced COVID-19 severity, but periodic boosts are required to counteract the decline in immunity. An accelerated rate of immune escape to vaccine-elicited immunity has been associated with Spike protein antigenic shifts, as seen i...

Descripción completa

Detalles Bibliográficos
Autores principales: Focosi, Daniele, Maggi, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692555/
https://www.ncbi.nlm.nih.gov/pubmed/36366586
http://dx.doi.org/10.3390/v14112488
_version_ 1784837296173875200
author Focosi, Daniele
Maggi, Fabrizio
author_facet Focosi, Daniele
Maggi, Fabrizio
author_sort Focosi, Daniele
collection PubMed
description The wild-type SARS-CoV-2 Spike-based vaccines authorized so far have reduced COVID-19 severity, but periodic boosts are required to counteract the decline in immunity. An accelerated rate of immune escape to vaccine-elicited immunity has been associated with Spike protein antigenic shifts, as seen in the Omicron variant of concern and its sublineages, demanding the development of Omicron Spike-based vaccines. Herein, we review the evidence in animal models and topline results from ongoing clinical trials with such updated vaccines, discussing the pros and cons for their deployment.
format Online
Article
Text
id pubmed-9692555
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96925552022-11-26 Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline Focosi, Daniele Maggi, Fabrizio Viruses Opinion The wild-type SARS-CoV-2 Spike-based vaccines authorized so far have reduced COVID-19 severity, but periodic boosts are required to counteract the decline in immunity. An accelerated rate of immune escape to vaccine-elicited immunity has been associated with Spike protein antigenic shifts, as seen in the Omicron variant of concern and its sublineages, demanding the development of Omicron Spike-based vaccines. Herein, we review the evidence in animal models and topline results from ongoing clinical trials with such updated vaccines, discussing the pros and cons for their deployment. MDPI 2022-11-10 /pmc/articles/PMC9692555/ /pubmed/36366586 http://dx.doi.org/10.3390/v14112488 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Opinion
Focosi, Daniele
Maggi, Fabrizio
Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline
title Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline
title_full Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline
title_fullStr Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline
title_full_unstemmed Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline
title_short Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline
title_sort do we really need omicron spike-based updated covid-19 vaccines? evidence and pipeline
topic Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692555/
https://www.ncbi.nlm.nih.gov/pubmed/36366586
http://dx.doi.org/10.3390/v14112488
work_keys_str_mv AT focosidaniele dowereallyneedomicronspikebasedupdatedcovid19vaccinesevidenceandpipeline
AT maggifabrizio dowereallyneedomicronspikebasedupdatedcovid19vaccinesevidenceandpipeline

Ejemplares similares